NCT03778931 2025-09-15EMERALDStemline Therapeutics, Inc.Phase 3 Completed478 enrolled 16 charts 1 FDA
NCT04797728 2022-10-26ELIPSESOLTI Breast Cancer Research GroupPhase EARLY_PHASE1 Completed23 enrolled
NCT02338349 2022-08-18A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast CancerStemline Therapeutics, Inc.Phase 1 Completed57 enrolled
NCT02650817 2022-08-18Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast CancerStemline Therapeutics, Inc.Phase 1 Completed16 enrolled